Peer-reviewed veterinary case report
Celecoxib slows growth of canine melanoma cells with or without COX-2
By Seo, Kyoung-Won et al.·Published in Research in veterinary science·2014·Department of Veterinary Internal Medicine, South Korea·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Antitumor effects of celecoxib in COX-2 expressing and non-expressing canine melanoma cell lines.
- Species:
- dog
Plain-English summary
A study found that celecoxib, a medication that blocks a specific enzyme, showed promise in fighting malignant melanoma, a serious type of oral cancer in dogs. The researchers tested celecoxib on two different canine melanoma cell lines and observed that it significantly slowed down the growth of cancer cells. This suggests that celecoxib could potentially be an effective treatment option for dogs diagnosed with this type of cancer. While more research is needed, these findings offer hope for better therapies for dogs suffering from malignant melanoma.
People also search for: dog melanoma treatment · celecoxib for dogs cancer · canine oral tumor therapy
Abstract
Cyclooxygenase-2 (COX-2) is a potential target for chemoprevention and cancer therapy. Celecoxib, a selective COX-2 inhibitor, inhibits cell growth of various types of human cancer including malignant melanoma. In dogs, oral malignant melanoma represents the most common oral tumor and is often a fatal disease. Therefore, there is a desperate need to develop additional therapeutic strategies. The purpose of this study was to investigate the anticancer effects of celecoxib on canine malignant melanoma cell lines that express varying levels of COX-2. Celecoxib induced a significant anti-proliferative effect in both LMeC and CMeC-1 cells. In the CMeC cells, treatment of 50 μM celecoxib caused an increase in cells in the G0/G1 and a decreased proportion of cells in G-2 phase. In the LMeC cells, 50 μM of celecoxib led to an increase in the percentage of cells in the sub-G1 phase and a significant activation of caspase-3 when compared to CMeC-1 cells. In conclusion, these results demonstrate that celecoxib exhibits antitumor effects on canine melanoma LMeC and CMeC-1 cells by induction of G1-S cell cycle arrest and apoptosis. Our data suggest that celecoxib might be effective as a chemotherapeutic agent against canine malignant melanoma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/24656746/